제품번호 | 종 | 제품 설명 | 구조 | 순도 | 특징 |
---|---|---|---|---|---|
MEK-H5253 | Human | Human MERTK / Mer Protein, Fc Tag | ![]() |
![]() ![]() |
|
MEK-C5253 | Cynomolgus | Cynomolgus MERTK / Mer Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
|
MEK-M5253 | Mouse | Mouse MERTK / Mer Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
|
MEK-H52H6 | Human | Human MERTK / Mer Protein, His Tag | ![]() |
![]() ![]() |
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
The purity of Mouse MERTK, Fc Tag (Cat. No. MEK-M5253) is more than 90% and the molecular weight of this protein is around 198-242 kDa verified by SEC-MALS.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Cabozantinib S-malate | XL-184; BMS-907351 | Approved | Exelixis Inc | Cometriq, Cabometyx | Japan | Carcinoma, Renal Cell | Takeda | 2012-11-29 | Thyroid Neoplasms; Adenocarcinoma, Follicular; Brain Neoplasms; Sarcoma; Neuroblastoma; Neurofibroma, Plexiform; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Bile Duct Neoplasms; Central Nervous System Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Glioma; Carcinoma, Neuroendocrine; Carcinoma, Hepatocellular; Neoplasms, Germ Cell and Embryonal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Thyroid Cancer, Papillary; Meningioma; Carcinoma, Transitional Cell; Kidney Neoplasms; Ovarian germ cell tumor; Bone metastases; Carcinoma, Renal Cell; Rejection of liver transplantation; Esophageal Neoplasms; Pain; Stomach Neoplasms; Carcinoma, Merkel Cell; Glioblastoma; Seminoma; Solid tumours; Neurofibromatoses; Neoplasms; Salivary Gland Neoplasms; Carcinoma, Papillary; Skin Neoplasms; Kidney Diseases; Neuroendocrine Tumors; Adrenocortical Carcinoma; Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
INCB-081776 | INCB-81776; INCB-081776 | Incyte Corp | Details | ||
MRX-2843 | MRX-2843; UNC-2025; UNC-2371 | Phase 1 Clinical | Meryx, University Of North Carolina At Chapel Hill, University Of Colorado At Denver | Solid tumours; Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.